SCC503
3dGRO® Human CRC Organoids (ISO49)
Synonyme(s) :
3dGRO® Human CRC Organoids (ISO49)
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
41106509
Nomenclature NACRES :
NA.81
Produits recommandés
Source biologique
human
Conditionnement
pkg of >100,000 organoids vials
Fabricant/nom de marque
Sigma-Aldrich
Mode de croissance
N/A
Technique(s)
cell culture | mammalian: suitable
cell culture | stem cell: suitable
Conditions d'expédition
ambient
Température de stockage
−70°C
Description générale
Colorectal cancer accounts for roughly 10% of all cancer cases worldwide with more than half of all patients with CRC developing metastatic disease leading to death. Recently tissue derived organoids have emerged as a more predictive 3 dimensional cell culture model of disease. 3D organoid cultures conserve the original genetic and phenotypic characteristics of the primary tissue allowing for their application in many research fields included drug development, personalized medicine and potential therapeutics. In vitro cultured tumor organoids have also been shown to predict patient response to chemotherapeutics. PDOs derived from colorectal cancer (CRC organoids) have been used for cell modeling and to investigate the function of cancer related driver gene mutations including APC, TP53, KRAS, BRAF, PIK3CA etc.
3dGRO® Human CRC Organoids are offered in a ready-to-assay format intended to simplify the organoid cell culture workflow. A single vial of organoids is enough to directly thaw and seed into a 96-well plate without cell expansion for drug screening applications. The organoids are manufactured using Cellesce’s patented technology which enables the robust growth and expansion of patient-derived organoids (PDOs). Cellesce’s technology minimizes manual handling time to maximize reproducibility in order to position organoid cell models as a cost effective and accurate tool in early-stage drug discovery. The organoid biobank includes tumor derived colorectal cancer PDOs from a range of genetic backgrounds, driver gene mutations, tumor sites and cancer stages. These organoid cell lines have been well characterized and are all validated for response against a number of known CRC-targeting agents.
3dGRO® Human CRC Organoids are offered in a ready-to-assay format intended to simplify the organoid cell culture workflow. A single vial of organoids is enough to directly thaw and seed into a 96-well plate without cell expansion for drug screening applications. The organoids are manufactured using Cellesce’s patented technology which enables the robust growth and expansion of patient-derived organoids (PDOs). Cellesce’s technology minimizes manual handling time to maximize reproducibility in order to position organoid cell models as a cost effective and accurate tool in early-stage drug discovery. The organoid biobank includes tumor derived colorectal cancer PDOs from a range of genetic backgrounds, driver gene mutations, tumor sites and cancer stages. These organoid cell lines have been well characterized and are all validated for response against a number of known CRC-targeting agents.
Application
Cell Growth: Organoid expansion after 7 daysMycoplasma: NegativeViral Testing: Negative (HIV-1, HIV-2, HBV, CMV, EBV, HPV)Sterility (Bacteria, Yeast, Fungi): NegativeMutational Profile: APC ∆R1450*A1446Lfs*27, TP53 ∆R248Q, KRAS ∆G12D, PIK3CA ∆E542K, FBXW7 ∆R465C
Caractéristiques et avantages
Ready-to-Assay human colorectal cancer organoids for 3D cell culture applications.
Stockage et stabilité
Store 3dGRO® Human CRC Organoids at -80°C. For long term storage the cells should be stored in liquid nitrogen.
Informations légales
3dGRO is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Ce produit, destiné à la recherche scientifique, est soumis à une réglementation spécifique en France, y compris pour les activités d′importation et d′exportation (Article L 1211-1 alinéa 2 du Code de la Santé Publique). L′acheteur (c′est-à-dire l′utilisateur FINAL) est tenu d′obtenir une autorisation d′importation auprès du ministère français de la recherche, mentionné à l′article L1245-5-1 II du Code de la Santé Publique. En commandant ce produit, vous confirmez détenir l′autorisation d′importation requise.
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Luned M Badder et al.
PloS one, 15(8), e0235319-e0235319 (2020-08-19)
Aberrant activation of the Wnt signalling pathway is required for tumour initiation and survival in the majority of colorectal cancers. The development of inhibitors of Wnt signalling has been the focus of multiple drug discovery programs targeting colorectal cancer and
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique